DAIICHI SANKYO sets up subsidiary in Ireland Critical step in European expansion

26.11.08 - 02:58 ... source : Daiichi Sankyo

... Japanese pharmaceutical group has its own Irish affiliate Dublin, Nov. 25th, 2008 - DAIICHI SANKYO, the third-largest Japanese pharmaceutical group and one of the world's leading research-driven pharmaceutical companies, has established its own subsidiary in Ireland. As part of this effort, 14 employees from the cardiometabolic sales force at Merck Serono Ltd. are being transferred to DAIICHI SANKYO effective immediately. The company will be called DAIICHI SANKYO IRELAND Ltd. and be headquartered in Dublin. In addition to the osteoporosis medication Evista®(Raloxifen), DAIICHI SANKYO IRELAND Ltd. will market the anti-hypertensive product Cardicor®(Bisoprolol), for the treatment of cardiac insufficiency, as well as Emcor®(Bisoprolol) for the treatment of hypertension and angina pectoris. DAIICHI SANKYO IRELAND Ltd. will also sell the diabetes drug Glucophage®(Metformin) as part of a co-promot ...» Next (HTML)